GeoVax Reports Second Quarter 2026 Financial Results and Advances GEO-MVA Toward Pivotal Study

GeoVax Labs, Inc. (Nasdaq: GOVX) announced its financial results for the second quarter of 2026 and provided an update on its lead programs. The company is advancing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox, toward a planned pivotal immunobridging study expected to initiate in the fourth quarter of 2026. This study is supported by an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).

During the second quarter, GeoVax continued operational activities including clinical study readiness, manufacturing preparedness, and utilization of previously manufactured and released cGMP clinical trial material. The company also advanced its AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA vaccine production and engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.

"During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study," said David A. Dodd, Chairman and CEO of GeoVax. "Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense."

In addition to GEO-MVA, GeoVax continues to advance Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism may complement PD-1-based therapies like Merck's Keytruda by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.

Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, in the same period of 2025. Research and development expenses decreased to $3.1 million from $4.7 million, primarily due to lower costs associated with the terminated BARDA contract for the GEO-CM04S1 COVID-19 vaccine program. General and administrative expenses were $1.3 million, down from $1.5 million, reflecting lower investor relations costs and stock-based compensation. Cash and cash equivalents stood at $3.1 million as of June 30, 2026.

The company's strategic reprioritization, announced in May 2026, focuses resources on GEO-MVA and Gedeptin, discontinuing active development of the GEO-CM04S1 COVID-19 vaccine candidate due to market contraction. GeoVax believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity, supporting public health preparedness and biodefense resilience. More information is available on the company's website at https://www.geovax.com.